181 related articles for article (PubMed ID: 30114207)
1. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.
Gountas I; Sypsa V; Blach S; Razavi H; Hatzakis A
PLoS One; 2018; 13(8):e0202109. PubMed ID: 30114207
[TBL] [Abstract][Full Text] [Related]
2. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
[TBL] [Abstract][Full Text] [Related]
4. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
5. Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings.
Scott N; Sacks-Davis R; Pedrana A; Doyle J; Thompson A; Hellard M
J Viral Hepat; 2018 Dec; 25(12):1472-1480. PubMed ID: 30047625
[TBL] [Abstract][Full Text] [Related]
6. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
7. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
[TBL] [Abstract][Full Text] [Related]
8. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
[TBL] [Abstract][Full Text] [Related]
10. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
[TBL] [Abstract][Full Text] [Related]
11. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
[TBL] [Abstract][Full Text] [Related]
12. Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.
Scott N; Hellard M; McBryde ES
Virulence; 2016; 7(2):201-8. PubMed ID: 26305706
[TBL] [Abstract][Full Text] [Related]
13. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium.
Matheï C; Bourgeois S; Blach S; Brixko C; Mulkay JP; Razavi H; Robaeys G
Acta Gastroenterol Belg; 2016; 79(2):227-32. PubMed ID: 27382943
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.
Zelenev A; Li J; Mazhnaya A; Basu S; Altice FL
Lancet Infect Dis; 2018 Feb; 18(2):215-224. PubMed ID: 29153265
[TBL] [Abstract][Full Text] [Related]
15. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
[TBL] [Abstract][Full Text] [Related]
16. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
Scott N; McBryde E; Vickerman P; Martin NK; Stone J; Drummer H; Hellard M
BMC Med; 2015 Aug; 13():198. PubMed ID: 26289050
[TBL] [Abstract][Full Text] [Related]
17. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance.
Rosińska M; Sierosławski J; Wiessing L
BMC Infect Dis; 2015 Feb; 15():83. PubMed ID: 25879904
[TBL] [Abstract][Full Text] [Related]
18. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination.
Kåberg M; Navér G; Hammarberg A; Weiland O
J Viral Hepat; 2018 Dec; 25(12):1452-1461. PubMed ID: 29998522
[TBL] [Abstract][Full Text] [Related]
19. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
[TBL] [Abstract][Full Text] [Related]
20. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
Bruggmann P; Grebely J
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
